PolyPid Unveils Phase 3 SHIELD II Trial Results for D-PLEX100

PolyPid to Showcase Promising Phase 3 SHIELD II Results

PETACH TIKVA, Israel — PolyPid Ltd. (Nasdaq: PYPD), a pioneering biopharma company focused on enhancing surgical outcomes, is thrilled to announce that Dr. Shmuel Sharoni will present the positive topline results of the Company's Phase 3 SHIELD II trial of D-PLEX???. This significant event will take place at the upcoming American College of Surgeons (ACS) Clinical Congress.

Overview of the Presentation

Dr. Sharoni's presentation, titled "Efficacy Of A Novel Local Prolonged-release Incisional Doxycycline On Surgical Site Infection Prophylaxis In Abdominal Colorectal Surgery: The SHIELD II Phase 3 Randomized Clinical Trial," is scheduled for a high-impact session on a specified date. This session promises to provide insights into how D-PLEX??? can vastly improve patient care.

Conference Details for Attendees

The 2025 ACS Clinical Congress will be hosted at McCormick Place and will run from October 4 to October 7. Dr. Sharoni's engaging presentation is set for October 5 at 11:30 AM CT as part of the "High Impact Clinical Trials and Studies" session. This is an excellent opportunity for healthcare professionals and stakeholders in the surgical field to learn about groundbreaking advances in infection prophylaxis.

Meet the PolyPid Team

The PolyPid management team invites attendees to connect for discussions and inquiries regarding their recent findings and future plans. Reach out via the designated email for questions or to arrange a meeting during this prominent event.

Introducing the SHIELD II Trial

The SHIELD II trial was a well-structured, multinational study designed to gauge the effectiveness of D-PLEX??? in a controlled, randomized fashion. This double-blind study marked a significant milestone by successfully meeting its primary and secondary efficacy endpoints. The findings revealed a remarkable 38% reduction in surgical site infections, as well as reinterventions or mortality risk when D-PLEX??? was used alongside standard care. Specifically, this trial reported a striking 58% reduction in surgical site infections attributable to D-PLEX???.

About PolyPid Ltd.

PolyPid Ltd. operates at the forefront of biopharma innovation (Nasdaq: PYPD). The Company aims to transform surgical care through prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology facilitates precise and controlled drug delivery, ensuring effective treatment over extended periods. Following the encouraging results from the Phase 3 trial, PolyPid plans to pursue a New Drug Application (NDA) for D-PLEX??? in early 2026, reinforcing their commitment to addressing infection risks in colorectal surgeries. Furthermore, PolyPid is developing solutions across diverse medical challenges including oncology, obesity, and diabetes.

Additional Information

If you would like to learn more about PolyPid and its initiatives, please visit their official website or connect with them on social media platforms for the latest updates.

Frequently Asked Questions

What is the Phase 3 SHIELD II trial about?

The SHIELD II trial evaluates the efficacy of D-PLEX??? in reducing surgical site infections in colorectal surgeries.

When will the trial results be presented?

The topline results will be presented at the ACS Clinical Congress on October 5, 2025.

How effective was D-PLEX??? compared to standard care?

D-PLEX??? demonstrated a 38% reduction in surgical site infections, reinterventions, or mortality compared to standard care.

What is the next step for PolyPid following the trial results?

PolyPid plans to submit a New Drug Application (NDA) for D-PLEX??? in early 2026 based on the positive trial outcomes.

What other applications is PolyPid exploring?

In addition to surgical care, PolyPid is developing innovative solutions in oncology, obesity, and diabetes.

About The Author

Hello, my name is Ryan Hughes. I am a financial, economics, and stock market specialist committed to assisting people in negotiating the intricacies of the financial system. Having a great deal of experience and a thorough grasp of market dynamics and economic trends, my area of expertise is converting complex financial ideas into understandable, practical knowledge. By use of my articles and blog entries, I hope to give you the information and assurance you need to make wise financial choices.

I've had the honor of interacting with a wide range of readers as a writer for several financial blogs, from new investors to seasoned market participants. To enable you to reach your financial goals, I want to make finance, economics, and stock market trends understandable and approachable. I appreciate you traveling with me toward success and financial literacy.

Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.